TY - JOUR
T1 - Role of Statins in Glucose Homeostasis and Insulin Resistance
AU - Dahagam, Chanukya
AU - Hahn, Virginia S.
AU - Goud, Aditya
AU - D’Souza, Jason
AU - Abdelqader, Abdelhai
AU - Blumenthal, Roger S.
AU - Martin, Seth S.
N1 - Publisher Copyright:
© 2016, Springer Science+Business Media New York.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Statins are widely used for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD), and, under the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol treatment guidelines, more individuals are eligible for statin therapy. In this review, we summarize evidence for a mild increase in serum glucose and increased incidence of diabetes associated with statins, the hypothesized mechanisms by which statins may impair glucose homeostasis, the risk of diabetes associated with particular statins, and the net effect on ASCVD risk. As emphasized by the ACC/AHA guideline group and other experts, the risk-reducing benefits of statin therapy generally outweigh the mild rise in glucose levels or new diagnoses of diabetes. As such, an appropriate balancing of benefits and risks is critical in clinical practice as clinicians engage patients in shared decision making. Moreover, when discussing statins and risk of diabetes, this is a prime opportunity for clinicians to provide further counseling on the central importance of weight loss and adhering to a healthy lifestyle in glucose homeostasis and diabetes prevention.
AB - Statins are widely used for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD), and, under the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol treatment guidelines, more individuals are eligible for statin therapy. In this review, we summarize evidence for a mild increase in serum glucose and increased incidence of diabetes associated with statins, the hypothesized mechanisms by which statins may impair glucose homeostasis, the risk of diabetes associated with particular statins, and the net effect on ASCVD risk. As emphasized by the ACC/AHA guideline group and other experts, the risk-reducing benefits of statin therapy generally outweigh the mild rise in glucose levels or new diagnoses of diabetes. As such, an appropriate balancing of benefits and risks is critical in clinical practice as clinicians engage patients in shared decision making. Moreover, when discussing statins and risk of diabetes, this is a prime opportunity for clinicians to provide further counseling on the central importance of weight loss and adhering to a healthy lifestyle in glucose homeostasis and diabetes prevention.
KW - Cardiovascular disease
KW - Cholesterol
KW - Diabetes
KW - Hyperglycemia
KW - Insulin resistance
KW - Statins
UR - http://www.scopus.com/inward/record.url?scp=84992390299&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992390299&partnerID=8YFLogxK
U2 - 10.1007/s12170-016-0523-4
DO - 10.1007/s12170-016-0523-4
M3 - Review article
AN - SCOPUS:84992390299
SN - 1932-9520
VL - 10
JO - Current Cardiovascular Risk Reports
JF - Current Cardiovascular Risk Reports
IS - 12
M1 - 40
ER -